Clinical Trials Browser

Terminated × Interventional × sapanisertib × Clear all

NCT05275673 2025-04-24

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Phase 2 Terminated

7 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

NCT02133183 2024-04-04

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

Phase 1 Terminated

Glioblastoma, Gliosarcoma

NCT03370302 2023-02-08

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Phase 1 Terminated

28 enrolled 33 charts

Advanced Nonhematological Neoplasms

NCT02987959 2022-10-14

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Phase 2 Terminated

6 enrolled 10 charts

Sarcoma

NCT02601209 2022-08-23

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Phase 1/2 Terminated

151 enrolled 22 charts

Leiomyosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT02575339 2022-07-26

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Phase 1/2 Terminated

11 enrolled 15 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02727777 2020-03-12

Phase II Study of TAK228 in Relapsed Lymphoma

Phase 1/2 Terminated

4 enrolled 9 charts

Lymphoma